Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials

Abstract Background: Diabetes mellitus is a severe chronic disease leading to systemic complications, including cardiovascular dysfunction. Previous cell therapy studies have obtained promising results with the use bone marrow mesenchymal stromal cells derived from healthy animals (MSCc) in diabetes animal models. However, the ability of MSC derived from diabetic rats to improve functional cardiac parameters is still unknown. Objectives: To investigate whether bone-marrow-derived MSC from diabetic rats (MSCd) would contribute to recover metabolic and cardiac electrical properties in other diabetic rats. Methods: Diabetes was induced in Wistar rats with streptozotocin. MSCs were characterized by flow cytometry, morphological analysis, and immunohistochemistry. Cardiac electrical function was analyzed using recordings of ventricular action potential. Differences between variables were considered significant when p < 0.05. Results: In vitro properties of MSCc and MSCd were evaluated. Both cell types presented similar morphology, growth kinetics, and mesenchymal profile, and could differentiate into adipogenic and osteogenic lineages. However, in an assay for fibroblast colony-forming units (CFU-F), MSCd formed more colonies than MSCc when cultured in expansion medium with or without hydrocortisone (1 µM). In order to compare the therapeutic potential of the cells, the animals were divided into four experimental groups: nondiabetic (CTRL), diabetic (DM), diabetic treated with MSCc (DM + MSCc), and diabetic treated with MSCd (DM + MSCd). The treated groups received a single injection of MSC 4 weeks after the development of diabetes. MSCc and MSCd controlled hyperglycemia and body weight loss and improved cardiac electrical remodeling in diabetic rats. Conclusions: MSCd and MSCc have similar in vitro properties and therapeutic potential in a rat model of diabetes induced with streptozotocin.

Saved in:
Bibliographic Details
Main Authors: José,Vitória Santório de São, Monnerat,Gustavo, Guerra,Barbara, Paredes,Bruno Dias, Kasai-Brunswick,Tais Hanae, Carvalho,Antonio Carlos Campos de, Medei,Emiliano
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Cardiologia - SBC 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001500579
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0066-782X2017001500579
record_format ojs
spelling oai:scielo:S0066-782X20170015005792018-01-19Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic PotentialsJosé,Vitória Santório de SãoMonnerat,GustavoGuerra,BarbaraParedes,Bruno DiasKasai-Brunswick,Tais HanaeCarvalho,Antonio Carlos Campos deMedei,Emiliano Diabetes Mellitus Mesenchymal Stromal Cells Cardiac Electrophysiology Cell and Tissue-Based Therapy Rats Abstract Background: Diabetes mellitus is a severe chronic disease leading to systemic complications, including cardiovascular dysfunction. Previous cell therapy studies have obtained promising results with the use bone marrow mesenchymal stromal cells derived from healthy animals (MSCc) in diabetes animal models. However, the ability of MSC derived from diabetic rats to improve functional cardiac parameters is still unknown. Objectives: To investigate whether bone-marrow-derived MSC from diabetic rats (MSCd) would contribute to recover metabolic and cardiac electrical properties in other diabetic rats. Methods: Diabetes was induced in Wistar rats with streptozotocin. MSCs were characterized by flow cytometry, morphological analysis, and immunohistochemistry. Cardiac electrical function was analyzed using recordings of ventricular action potential. Differences between variables were considered significant when p < 0.05. Results: In vitro properties of MSCc and MSCd were evaluated. Both cell types presented similar morphology, growth kinetics, and mesenchymal profile, and could differentiate into adipogenic and osteogenic lineages. However, in an assay for fibroblast colony-forming units (CFU-F), MSCd formed more colonies than MSCc when cultured in expansion medium with or without hydrocortisone (1 µM). In order to compare the therapeutic potential of the cells, the animals were divided into four experimental groups: nondiabetic (CTRL), diabetic (DM), diabetic treated with MSCc (DM + MSCc), and diabetic treated with MSCd (DM + MSCd). The treated groups received a single injection of MSC 4 weeks after the development of diabetes. MSCc and MSCd controlled hyperglycemia and body weight loss and improved cardiac electrical remodeling in diabetic rats. Conclusions: MSCd and MSCc have similar in vitro properties and therapeutic potential in a rat model of diabetes induced with streptozotocin.info:eu-repo/semantics/openAccessSociedade Brasileira de Cardiologia - SBCArquivos Brasileiros de Cardiologia v.109 n.6 20172017-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001500579en10.5935/abc.20170176
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author José,Vitória Santório de São
Monnerat,Gustavo
Guerra,Barbara
Paredes,Bruno Dias
Kasai-Brunswick,Tais Hanae
Carvalho,Antonio Carlos Campos de
Medei,Emiliano
spellingShingle José,Vitória Santório de São
Monnerat,Gustavo
Guerra,Barbara
Paredes,Bruno Dias
Kasai-Brunswick,Tais Hanae
Carvalho,Antonio Carlos Campos de
Medei,Emiliano
Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
author_facet José,Vitória Santório de São
Monnerat,Gustavo
Guerra,Barbara
Paredes,Bruno Dias
Kasai-Brunswick,Tais Hanae
Carvalho,Antonio Carlos Campos de
Medei,Emiliano
author_sort José,Vitória Santório de São
title Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
title_short Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
title_full Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
title_fullStr Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
title_full_unstemmed Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
title_sort bone-marrow-derived mesenchymal stromal cells (msc) from diabetic and nondiabetic rats have similar therapeutic potentials
description Abstract Background: Diabetes mellitus is a severe chronic disease leading to systemic complications, including cardiovascular dysfunction. Previous cell therapy studies have obtained promising results with the use bone marrow mesenchymal stromal cells derived from healthy animals (MSCc) in diabetes animal models. However, the ability of MSC derived from diabetic rats to improve functional cardiac parameters is still unknown. Objectives: To investigate whether bone-marrow-derived MSC from diabetic rats (MSCd) would contribute to recover metabolic and cardiac electrical properties in other diabetic rats. Methods: Diabetes was induced in Wistar rats with streptozotocin. MSCs were characterized by flow cytometry, morphological analysis, and immunohistochemistry. Cardiac electrical function was analyzed using recordings of ventricular action potential. Differences between variables were considered significant when p < 0.05. Results: In vitro properties of MSCc and MSCd were evaluated. Both cell types presented similar morphology, growth kinetics, and mesenchymal profile, and could differentiate into adipogenic and osteogenic lineages. However, in an assay for fibroblast colony-forming units (CFU-F), MSCd formed more colonies than MSCc when cultured in expansion medium with or without hydrocortisone (1 µM). In order to compare the therapeutic potential of the cells, the animals were divided into four experimental groups: nondiabetic (CTRL), diabetic (DM), diabetic treated with MSCc (DM + MSCc), and diabetic treated with MSCd (DM + MSCd). The treated groups received a single injection of MSC 4 weeks after the development of diabetes. MSCc and MSCd controlled hyperglycemia and body weight loss and improved cardiac electrical remodeling in diabetic rats. Conclusions: MSCd and MSCc have similar in vitro properties and therapeutic potential in a rat model of diabetes induced with streptozotocin.
publisher Sociedade Brasileira de Cardiologia - SBC
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001500579
work_keys_str_mv AT josevitoriasantoriodesao bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT monneratgustavo bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT guerrabarbara bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT paredesbrunodias bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT kasaibrunswicktaishanae bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT carvalhoantoniocarloscamposde bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
AT medeiemiliano bonemarrowderivedmesenchymalstromalcellsmscfromdiabeticandnondiabeticratshavesimilartherapeuticpotentials
_version_ 1756382051346415616